Pharma Mar, S.A. (PHMe)

Overview

Pharma Mar, S.A. is a globally operating biopharmaceutical firm headquartered in Madrid, Spain, with a focus on oncology. Established in 1986, the company is dedicated to the discovery, development, production, and marketing of bio-active principles primarily for cancer treatment. It operates across different regions including Spain, Italy, Germany, Ireland, France, the rest of the European Union, the United States, and beyond. Its business is structured into two key segments: Oncology and RNA Interference, highlighting its comprehensive approach towards treating cancer and its commitment to cutting-edge research in gene expression.

Products and Services

• Yondelis:

  A pioneering treatment developed for soft tissue sarcoma and ovarian cancer, showcasing Pharma Mar's commitment to providing options for complex cancers.

• Aplidin:

  A therapeutic agent for R/R multiple myeloma, Aplidin represents Pharma Mar's focus on addressing hard-to-treat cancers with innovative solutions.

• Zepzelca:

  This product is geared towards treating patients with small cell lung cancer, further illustrating the company’s dedication to covering a broad spectrum of oncology needs.

• PM14 (Ecubectedin):

  Currently in Phase II clinical trials for solid tumors, and in Phase I for soft tissue sarcoma and prostate cancer, PM14 is a testament to Pharma Mar's ongoing research and development efforts.

• PM534:

  In Phase I clinical trials for solid tumors, PM534 exemplifies the company's commitment to exploring new avenues for cancer treatment.

• PM54:

  Also in Phase I clinical trials for solid tumors, affirming Pharma Mar's robust pipeline and its relentless pursuit of innovative cancer therapies.

• SYL1801:

  Undergoing Phase II clinical trials for macular degeneration, this product highlights Pharma Mar's expansion into treatments beyond oncology, specifically ocular diseases.

• SYL116011:

  Currently in preclinical studies for ocular allergies, showcasing the company's commitment to addressing a range of ocular conditions.

• SYL A and B:

  Involved in investigational studies to treat retinitis pigmentosa, demonstrating Pharma Mar's dedication to exploring treatments for genetic disorders affecting vision.

In addition, Pharma Mar is actively engaged in the research, development, production, and sale of products aimed at reducing or silencing gene expression, reflecting its forefront position in RNA interference and gene therapy.